A major breakthrough in January 2026 is the FDA approval of the first at-home neurostimulation headsets (e.g., Flow

Neuroscience FL-100) for treating Major Depressive Disorder.

• tDCS Technology: These devices deliver a mild electrical current to the brain’s frontal lobe to regulate mood.

• Remote Supervision: The treatment is self-administered at home but is strictly "unlocked" and monitored by a therapist through a telehealth app, ensuring the patient follows the prescribed stimulation schedule.